cabotegravir/rilpivirine

Generic Name: cabotegravir-rilpivirine cabotegravir sodium

Brand Name: TBC

Manufacturer: ViiV Healthcare ULC

Indications: HIV-1 infection

Manufacturer Requested Reimbursement Criteria¹: cabotegravir-rilpivirine is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL). cabotegravir sodium is indicated in combination with EDURANT (rilpivirine) as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL).

Submission Type: New Combination

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.